Hanmi’s Poziotinib proved innovative efficacy for NSCLC patients
The advanced clinical result of ‘Poziotinib,’ a novel anticancer drug developed by Hanmi Pharm and licensed to Spectrum Pharmaceuticals, was revealed on the 18th at the World Conference on Lung Cancer(WCLC) in Yokohama, Japan.
Dr. John Heymach from the University of Texas MD Anderson Cancer Cent...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.